O	0	1	A
O	2	12	randomised
O	13	18	trial
O	19	21	of
O	22	31	secondary
O	32	43	prophylaxis
O	44	49	using
B-intervention	50	61	granulocyte
I-intervention	62	68	colony
I-intervention	68	69	-
I-intervention	69	80	stimulating
I-intervention	81	87	factor
O	88	89	(
O	89	90	'
O	90	95	SPROG
O	95	96	'
O	97	102	trial
O	102	103	)
O	104	107	for
O	108	119	maintaining
O	120	124	dose
O	125	134	intensity
O	135	137	of
O	138	146	standard
O	147	155	adjuvant
O	156	168	chemotherapy
O	169	172	for
O	173	179	breast
O	180	186	cancer
O	187	189	by
O	190	193	the
O	194	199	Anglo
O	199	200	-
O	200	206	Celtic
O	207	218	Cooperative
O	219	224	Group
O	225	228	and
O	229	233	NCRN
O	233	234	.

O	235	245	Guidelines
O	246	248	on
O	249	252	the
O	253	256	use
O	257	259	of
O	260	274	haematopoietic
O	275	281	colony
O	281	282	-
O	282	293	stimulating
O	294	301	factors
O	302	305	for
O	306	314	patients
O	315	321	having
O	322	330	adjuvant
O	331	343	chemotherapy
O	344	347	for
O	348	354	breast
O	355	361	cancer
O	362	365	are
O	366	374	designed
O	375	377	to
O	378	386	minimise
O	387	390	the
O	391	395	risk
O	396	398	of
O	399	411	neutropaenic
O	412	421	infection
O	422	423	(
O	423	428	Smith
O	429	431	TJ
O	431	432	,
O	433	447	Khatcheressian
O	448	449	J
O	449	450	,
O	451	456	Lyman
O	457	459	GH
O	460	462	et
O	463	465	al
O	465	466	.
O	467	473	Update
O	474	476	of
O	477	492	recommendations
O	493	496	for
O	497	500	the
O	501	504	use
O	505	507	of
O	508	513	white
O	514	519	blood
O	520	524	cell
O	525	531	growth
O	532	539	factors
O	539	540	:
O	541	543	an
O	544	552	evidence
O	552	553	-
O	553	558	based
O	559	567	clinical
O	568	576	practice
O	577	586	guideline
O	586	587	.
O	588	589	J
O	590	594	Clin
O	595	600	Oncol
O	601	605	2006
O	605	606	;
O	607	608	3
O	608	609	:
O	610	613	187
O	613	614	-
O	614	617	205
O	617	618	;
O	619	624	Aapro
O	625	627	MS
O	627	628	,
O	629	636	Bohlius
O	637	638	J
O	638	639	,
O	640	647	Cameron
O	648	650	DA
O	651	653	et
O	654	656	al
O	656	657	.
O	658	664	Effect
O	665	667	of
O	668	675	primary
O	676	688	prophylactic
O	689	690	G
O	690	691	-
O	691	694	CSF
O	695	698	use
O	699	701	on
O	702	710	systemic
O	711	718	therapy
O	719	733	administration
O	734	737	for
O	738	745	elderly
O	746	752	breast
O	753	759	cancer
O	760	768	patients
O	768	769	.
O	770	776	Breast
O	777	783	Cancer
O	784	787	Res
O	788	793	Treat
O	794	798	2011
O	798	799	;
O	800	802	47
O	802	803	:
O	804	805	8
O	805	806	-
O	806	808	32
O	808	809	;
O	810	817	Carlson
O	818	820	RW
O	820	821	,
O	822	828	Allred
O	829	831	DC
O	831	832	,
O	833	841	Anderson
O	842	844	BO
O	845	847	et
O	848	850	al
O	850	851	.
O	852	858	Breast
O	859	865	cancer
O	865	866	.
O	867	875	Clinical
O	876	884	practice
O	885	895	guidelines
O	896	898	in
O	899	907	oncology
O	907	908	.
O	909	910	J
O	911	915	Natl
O	916	921	Compr
O	922	926	Canc
O	927	931	Netw
O	932	936	2009
O	936	937	;
O	938	939	7
O	939	940	:
O	941	944	122
O	944	945	-
O	945	948	192
O	948	949	)
O	949	950	.

O	951	954	Non
O	954	955	-
O	955	965	randomised
O	966	970	data
O	971	978	suggest
O	979	983	that
O	984	987	the
O	988	999	achievement
O	1000	1002	of
O	1003	1010	planned
O	1011	1015	dose
O	1016	1025	intensity
O	1026	1027	(
O	1027	1029	DI
O	1029	1030	)
O	1031	1034	may
O	1035	1039	have
O	1040	1042	an
O	1043	1052	important
O	1053	1059	effect
O	1060	1062	on
O	1063	1071	survival
O	1071	1072	.

O	1073	1077	This
O	1078	1083	trial
O	1084	1092	compared
O	1093	1096	the
O	1097	1104	effects
O	1105	1107	of
O	1108	1119	granulocyte
O	1120	1126	colony
O	1126	1127	-
O	1127	1138	stimulating
O	1139	1145	factor
O	1145	1146	,
O	1147	1151	GCSF
O	1151	1152	,
O	1153	1160	against
O	1161	1169	standard
O	1170	1180	management
O	1181	1190	following
O	1191	1192	a
O	1193	1198	first
O	1199	1211	neutropaenic
O	1212	1217	event
O	1218	1219	(
O	1219	1221	NE
O	1221	1222	)
O	1223	1225	in
O	1226	1235	achieving
O	1236	1243	planned
O	1244	1246	DI
O	1246	1247	.

B-eligibility	1248	1253	Adult
I-eligibility	1254	1262	patients
I-eligibility	1263	1272	receiving
I-eligibility	1273	1281	adjuvant
I-eligibility	1282	1284	or
I-eligibility	1285	1296	neoadjuvant
I-eligibility	1297	1309	chemotherapy
O	1310	1314	were
O	1315	1325	randomised
O	1326	1335	following
O	1336	1337	a
O	1338	1343	first
O	1344	1346	NE
O	1346	1347	,
O	1348	1355	defined
O	1356	1358	as
O	1359	1374	hospitalisation
O	1375	1378	due
O	1379	1381	to
O	1382	1394	neutropaenic
O	1395	1400	fever
O	1400	1401	,
O	1402	1404	an
O	1405	1413	absolute
O	1414	1424	neutrophil
O	1425	1430	count
O	1431	1432	(
O	1432	1435	ANC
O	1435	1436	)
O	1437	1438	≤
O	1438	1439	1
O	1439	1440	.
O	1440	1441	5
O	1442	1443	×
O	1444	1446	10
O	1446	1447	(
O	1447	1448	9
O	1448	1449	)
O	1449	1450	/
O	1450	1451	l
O	1452	1461	requiring
O	1462	1471	treatment
O	1472	1477	delay
O	1478	1480	or
O	1481	1485	dose
O	1486	1495	reduction
O	1496	1498	of
O	1499	1501	15
O	1501	1502	%
O	1503	1505	or
O	1506	1510	more
O	1511	1513	of
O	1514	1521	planned
O	1522	1526	dose
O	1526	1527	.

O	1528	1531	The
O	1532	1537	study
O	1538	1541	was
O	1542	1551	initially
O	1552	1559	planned
O	1560	1562	to
O	1563	1568	enrol
O	1569	1572	816
O	1573	1581	patients
O	1582	1584	to
O	1585	1591	detect
O	1592	1593	a
O	1594	1604	difference
O	1605	1607	of
O	1608	1610	10
O	1610	1611	%
O	1611	1612	.

O	1613	1617	This
O	1618	1621	was
O	1622	1631	difficult
O	1632	1634	to
O	1635	1642	achieve
O	1643	1645	in
O	1646	1649	the
O	1650	1659	timeframe
O	1660	1663	and
O	1664	1667	the
O	1668	1673	trial
O	1674	1678	size
O	1679	1682	was
O	1683	1690	amended
O	1690	1691	.

O	1692	1696	Thus
O	1696	1697	,
B-total-participants	1698	1701	407
O	1702	1710	patients
O	1711	1715	were
O	1716	1724	randomly
O	1725	1733	assigned
O	1734	1736	to
O	1737	1747	filgrastim
O	1748	1751	for
O	1752	1753	7
O	1754	1758	days
O	1759	1761	or
O	1762	1775	pegfilgrastim
O	1776	1782	versus
B-control	1783	1791	standard
I-control	1792	1796	care
O	1796	1797	.

O	1798	1801	The
O	1802	1809	amended
O	1810	1815	study
O	1816	1819	was
O	1820	1828	designed
O	1829	1831	to
O	1832	1836	have
O	1837	1839	80
O	1839	1840	%
O	1841	1846	power
O	1847	1849	to
O	1850	1856	detect
O	1857	1859	an
O	1860	1868	absolute
O	1869	1879	difference
O	1880	1882	of
O	1883	1885	14
O	1885	1886	%
O	1887	1889	of
O	1890	1897	planned
O	1898	1900	DI
O	1901	1908	between
O	1909	1912	the
O	1913	1916	two
O	1917	1923	groups
O	1923	1924	.

O	1925	1929	Most
O	1930	1938	regimens
O	1939	1943	were
O	1944	1957	anthracycline
O	1957	1958	-
O	1958	1963	based
O	1964	1968	many
O	1969	1971	of
O	1972	1977	which
O	1978	1986	included
O	1987	1988	a
O	1989	1999	sequential
O	2000	2006	taxane
O	2007	2010	and
O	2010	2011	/
O	2011	2013	or
O	2014	2018	were
O	2019	2021	in
O	2022	2030	clinical
O	2031	2037	trials
O	2037	2038	.

O	2039	2045	Around
O	2046	2048	82
O	2048	2049	.
O	2049	2050	7
O	2050	2051	%
O	2052	2055	had
O	2056	2058	an
B-outcome	2059	2061	NE
O	2062	2064	in
O	2065	2068	the
O	2069	2074	first
O	2075	2080	three
O	2081	2087	cycles
O	2087	2088	.

O	2089	2090	A
O	2091	2096	total
O	2097	2099	of
O	2100	2103	401
O	2104	2107	had
O	2108	2118	calculable
B-outcome	2119	2127	relative
I-outcome	2128	2132	dose
I-outcome	2133	2142	intensity
I-outcome	2143	2144	(
I-outcome	2144	2147	RDI
I-outcome	2147	2148	)
O	2149	2153	data
O	2153	2154	.

O	2155	2156	A
O	2157	2163	target
O	2164	2166	of
O	2167	2169	85
O	2169	2170	%
O	2171	2178	planned
B-outcome	2179	2182	RDI
O	2183	2186	was
O	2187	2195	achieved
O	2196	2198	in
O	2199	2203	only
B-cv-bin-percent	2204	2206	50
I-cv-bin-percent	2206	2207	%
O	2208	2210	of
O	2211	2219	patients
O	2220	2222	in
O	2223	2226	the
O	2227	2234	control
O	2235	2238	arm
O	2239	2247	compared
O	2248	2252	with
B-iv-bin-percent	2253	2255	75
I-iv-bin-percent	2255	2256	%
O	2257	2259	in
O	2260	2263	the
O	2264	2268	GCSF
O	2269	2272	arm
O	2273	2274	(
O	2274	2275	P
O	2276	2277	<
O	2278	2279	0
O	2279	2280	.
O	2280	2284	0001
O	2284	2285	)
O	2285	2286	.

O	2287	2288	A
O	2289	2298	secondary
O	2299	2302	end
O	2303	2308	point
O	2309	2317	revealed
O	2318	2319	a
B-outcome	2320	2329	reduction
I-outcome	2330	2332	in
I-outcome	2333	2337	post
I-outcome	2337	2338	-
I-outcome	2338	2351	randomisation
I-outcome	2352	2355	NEs
O	2355	2356	,
B-cv-bin-percent	2357	2359	65
I-cv-bin-percent	2359	2360	.
I-cv-bin-percent	2360	2361	7
I-cv-bin-percent	2361	2362	%
O	2363	2371	controls
O	2372	2378	versus
B-iv-bin-percent	2379	2381	18
I-iv-bin-percent	2381	2382	.
I-iv-bin-percent	2382	2383	2
I-iv-bin-percent	2383	2384	%
O	2385	2389	with
O	2390	2394	GCSF
O	2394	2395	.

O	2396	2405	Secondary
O	2406	2418	intervention
O	2419	2423	with
O	2424	2428	GCSF
O	2429	2435	showed
O	2436	2437	a
O	2438	2451	statistically
O	2452	2463	significant
O	2464	2475	improvement
O	2476	2478	in
O	2479	2482	the
O	2483	2494	achievement
O	2495	2497	of
O	2498	2506	adequate
O	2507	2510	RDI
O	2511	2513	in
O	2514	2517	non
O	2517	2518	-
O	2518	2527	intensive
O	2528	2536	regimens
O	2536	2537	.

O	2538	2542	This
O	2543	2546	may
O	2547	2551	have
O	2552	2561	important
O	2562	2570	clinical
O	2571	2583	implications
O	2584	2587	for
O	2588	2595	outcome
O	2595	2596	.
